Elon's Vision
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Editor's Pick

Trump’s 100-Day Health Scorecard: Mixed Signals and Missed Marks

by
April 30, 2025
in Editor's Pick
0
Trump’s 100-Day Health Scorecard: Mixed Signals and Missed Marks
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Jeffrey A. Singer

With Representative Jason Smith (R‑MO) telling NewsNation’s Chris Stirewalt that President Donald Trump does not want his “one big beautiful bill” to focus on health care, one might assume the administration’s first 100 days had little impact on health policy. But a closer look shows otherwise.

President Trump’s executive order to withdraw the US from the World Health Organization responds to the organization’s politicization and mission creep. While the government has a legitimate role in public health, the WHO and some domestic agencies have drifted into personal health matters, often with ideological bias. Withdrawal could pressure the WHO to reassess and reform, possibly allowing a future US return; if not, the US can pursue better ways to coordinate internationally.

Staff cuts at the Department of Health and Human Services, the Food and Drug Administration, and the National Institutes of Health have mostly positive implications, but details matter. Reducing personnel who approve new drugs and devices risks delaying patient access. However, downsizing the FDA’s Center for Tobacco Products and the CDC’s Office of Smoking and Health helps curb their mission creep into personal health. 

Withdrawing the Biden administration’s proposed ban on menthol cigarettes and cigars is similarly a step in the right direction, eliminating the risk of exacerbating disparate law enforcement outcomes. One drawback of closing the Center for Tobacco Products could be slower approval of nicotine e‑cigarettes, a proven tobacco harm reduction tool that remains obstructed.

HHS Secretary Robert Kennedy’s recent support for the measles, mumps, and rubella vaccine is welcome, but his promotion of Vitamin A’s unproven benefits risks misleading people into choosing it over vaccination, despite Vitamin A’s toxicity at high doses. Kennedy’s broader science messaging is also flawed; promising answers on autism’s causes by September 2025 shows a poor grasp of objective science and a simplistic view of complex health disorders.

If I had to grade Trump’s health policy so far, I’d give it a C: some smart reversals, a few worrying missteps, and plenty still to prove.

Previous Post

Trump’s First 100 Days: Health Policy

Next Post

What If There Were More than 30 Million Illegal Immigrants?

Next Post
What If There Were More than 30 Million Illegal Immigrants?

What If There Were More than 30 Million Illegal Immigrants?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

Microsoft Planner vs Trello: Which Project Management Tool is Better?

May 24, 2023
Nicole Kidman Joins Paycom Webinar and Podcast to Talk Leadership, Tech and Work-Life Balance 

Nicole Kidman Joins Paycom Webinar and Podcast to Talk Leadership, Tech and Work-Life Balance 

January 31, 2025

An update on the National Nature Assessment

April 23, 2025
Non-dom tax revenues branded ‘fantasy economics’ by former government economist

Non-dom tax revenues branded ‘fantasy economics’ by former government economist

0

0

0

0
Non-dom tax revenues branded ‘fantasy economics’ by former government economist

Non-dom tax revenues branded ‘fantasy economics’ by former government economist

December 15, 2025
‘Reeves’ Christmas tax’ creates big winners and losers as 2026 business rates shake-up hits retail

‘Reeves’ Christmas tax’ creates big winners and losers as 2026 business rates shake-up hits retail

December 15, 2025
Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

December 14, 2025
Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

December 14, 2025

Recent News

Non-dom tax revenues branded ‘fantasy economics’ by former government economist

Non-dom tax revenues branded ‘fantasy economics’ by former government economist

December 15, 2025
‘Reeves’ Christmas tax’ creates big winners and losers as 2026 business rates shake-up hits retail

‘Reeves’ Christmas tax’ creates big winners and losers as 2026 business rates shake-up hits retail

December 15, 2025
Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

December 14, 2025
Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

Northern Ireland faces new car shortages as Brexit rules bite under Windsor framework

December 14, 2025

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.